InflaRx (IFRX) Expected to Announce Earnings on Wednesday

InflaRx (NASDAQ:IFRX - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $0.03 million for the quarter.

InflaRx (NASDAQ:IFRX - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.18. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. On average, analysts expect InflaRx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

InflaRx Trading Down 9.6 %

IFRX traded down $0.16 on Wednesday, reaching $1.46. The stock had a trading volume of 112,361 shares, compared to its average volume of 231,748. The business's 50-day moving average price is $1.21 and its two-hundred day moving average price is $1.82. The company has a market cap of $97.68 million, a P/E ratio of -1.35 and a beta of 1.57. InflaRx has a 12-month low of $0.82 and a 12-month high of $2.82.

Analyst Ratings Changes

A number of research firms recently weighed in on IFRX. Cantor Fitzgerald initiated coverage on InflaRx in a report on Tuesday, April 29th. They issued an "overweight" rating and a $10.00 price target for the company. Guggenheim upped their target price on InflaRx from $7.00 to $10.00 and gave the stock a "buy" rating in a research note on Wednesday, March 26th. Finally, HC Wainwright reissued a "buy" rating and issued a $8.00 price target on shares of InflaRx in a research note on Friday, March 21st.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.